No. of Recommendations: 2
Reading this article and the stated talents and focus of Roche......one has to wonder if CABO might have found a potential partner in near future. I just don't see EXEL getting CABO to market by itself inclusive of all that is required outside of the science itself.

Sounds like Roche knows the business and can expedite the process.

Pure speculation of course but after reading this article, this sounds more encouraging to EXEL's opportunities......if it doesn't run out of money first.

http://seekingalpha.com/article/901801-exelixis-first-partne...

Fortunately for Exelixis, GDC-0973 represents Roche's main effort to protect its melanoma franchise. This guarantees an aggressive and efficient development program for the drug. Roche is 6 months behind GSK, but positive results should enable it to retain its presence in melanoma from 2015 onwards. In parallel, GDC-0973 is in several early stage combination trials.

Market ignores a major milestone - a buying opportunity

Exelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche.
Print the post Back To Top
No. of Recommendations: 2
hi Dumaflotchie,
interesting take - my reply is on the EXEL board - which is not overloaded with political themes and non-issues...
marsuculix
Print the post Back To Top
No. of Recommendations: 0
Thanks Marsuculix!

Here is a link to your post:

http://boards.fool.com/co-operation-with-roche-30299103.aspx...

Obviously, one could speculate more into this deal than there is but there continues to be "hints" of proof of concept with EXEL through the Roche collaboration, CABO response rates in various tumors.

I would also agree that with MTC FDA approval, that seems imminent, EXEL looks to be on more scientific sound footing.

It remains the financial and commercialization footing that still bothers many folks.
Print the post Back To Top
No. of Recommendations: 3
hi Dumaflotchie,
I basically agree with you!
To me, there is one big question:
Why did EXEL management decide diluting and debt financing before the PDUFA date? Or was it a strategical signal to Roche? Or did EXEL make this move in order to be in a stronger position vis à vis Roche?
I do not have an answer(s) yet, but I will make some "subcutaneous" investigation with my colleagues at Roche in Basel...
You will hear from me, okay!?
marsuculix
Print the post Back To Top